Our researchers are fighting the coronavirus pandemic with innovative approaches. With your donation you can support them in developing drugs and vaccines against the virus or in deciphering the mechanisms of disease development and progression. Here you can find out all about donation opportunities.
Learn more about how the HZI, with its translational focus, will help to facilitate a faster and more targeted approach when it comes to fighting and preventing existing, emerging or recurring infectious diseases.
Here you can find out more about the scientific results of the HZI in the research topics ”Bacterial and Viral Pathogens”, “Immune Response and Interventions” and “Anti-Infectives”.
Around 900 employees in research, administration and infrastructure, and about 220 visiting scientists from 40 different countries are employed at the Helmholtz Centre for Infection Research. To ensure top quality research we need top quality employees. Your creativity and innovative capabilities are the basis for the long-term success of our work. That's why we undertake a great deal to attract the best people to us. Learn more about this.
From 1 July 2023, Prof Josef Penninger takes over the Scientific Management of the Helmholtz Centre for Infection Research (HZI). Here you can find content and background information for media coverage. [read more]
The coronaviruses are a family of viruses that includes a series of very different pathogens. These viruses usually infect mammals, rodents, and birds, but only few coronaviruses adapted to humans. They did this with great success: About one third of all typical "common colds" and some cases of diarrhoea as well are caused by these RNA Viruses, which are the largest of their kind. We have compiled more information about the coronaviruses for you.
With the pathogen SARS-CoV-2, a novel virus that can cause respiratory diseases and pneumonia has been spreading worldwide since the end of 2019. Here we will keep you informed about current developments in research and provide answers to the most important questions.
HomePressVideos & PodcastsVideos
Results 19 to 27 of total 62
2023-06-21
In order to find new active ingredients for the treatment of infectious diseases, HIPS researchers are taking a close look at soil bacteria that are known to produce natural products with promising pharmaceutical properties. These are then tested in the laboratory for their efficacy against human pathogens and thus used to develop novel antibiotics. The greater the biological…
2023-06-17
Two projects each from the Hannover Medical School (MHH), the University Medical Center Göttingen (UMG) and the Helmholtz Centre for Infection Research (HZI) in Braunschweig presented their promising ideas with prospects for scaling and commercialisation at today's event. Prof Dr Michael Zeisberg, Dr Liat Hayardeny-Brück, Prof Dr Lutz Ackermann and their team can now rejoice as…
2023-06-13
To develop new therapeutics against infections, researchers depend on laboratory models that allow them to simulate and study the infection process. Such models are essential, especially in the early testing and development of active substances, in order to keep the number of necessary animal experiments as low as possible. In the case of biofilm-associated infections, these models…
2023-06-09
The research group of Inhoffen Medal 2023 winner Prof Jörn Piel investigates how structurally complex natural products are produced. “Prof Jörn Piel is an outstanding scientist who has done ground-breaking work on microbial natural products research. His molecular biology-based work, for example on uncultured bacteria, opens up new areas of research that have received and are…
2023-06-08
Each person's gut microbiome contains a specific community of microorganisms that normally remains stable for years. However, it can be thrown off balance by factors such as dietary changes, infections or medications. Antibiotics in particular have a strong influence on the microbiome. In response, microorganisms employ various resistance mechanisms, with individual bacterial…
